RDHL (Redhill Biopharma Ltd.) Stock Analysis - Hedge Fund Holdings
Redhill Biopharma Ltd. (RDHL) is a publicly traded Healthcare sector company. As of May 21, 2026, RDHL trades at $0.92 with a market cap of $4.85M and a P/E ratio of 0.00. RDHL moved -0.98% today. Year to date, RDHL is -34.36%; over the trailing twelve months it is -51.63%. Its 52-week range spans $0.71 to $9.25. Rallies surfaces RDHL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns RDHL stock?
Hedge funds tracked by Rallies that own RDHL include Two Sigma. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Redhill Biopharma Ltd..
RDHL Key Metrics
Key financial metrics for RDHL
Metric
Value
Price
$0.92
Market Cap
$4.85M
P/E Ratio
0.00
EPS
$0.00
Dividend Yield
0.00%
52-Week High
$9.25
52-Week Low
$0.71
Volume
0
Avg Volume
0
Revenue (TTM)
$0
Net Income
$0
Gross Margin
0.00%
Top Hedge Funds Holding RDHL
Two Sigma holds 13.03K shares of RDHL, changed +12.80% as of Jun 30, 2024.
Raday Gilead sold 15.74M (~$1.57K) on Apr 6, 2026.
RDHL Analyst Consensus
RDHL analyst coverage data. Average price target: $0.00.
Common questions about RDHL
Who owns RDHL stock?
Hedge funds tracked by Rallies that own RDHL include Two Sigma. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Redhill Biopharma Ltd..
Does Rallies show 13F holders for RDHL?
Yes. Rallies tracks hedge fund and 13F ownership data for RDHL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RDHL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RDHL. It does not provide personalized investment advice.